Tilray Shares Struggle to Find Footing Amid Persistent Headwinds

Tilray shares face pressure from investor skepticism over losses and shareholder dilution, despite a narrower adjusted loss and a new Carlsberg partnership.

The stock of cannabis producer Tilray continues to face significant downward pressure. Despite recent strategic announcements and a modestly improved quarterly performance, investor skepticism remains high. Concerns are primarily centered on ongoing losses and the potential for further shareholder dilution, raising questions about the most substantial drags on the equity.

Technical and Trading Weakness Persists

Monday's trading session saw Tilray shares decline by 2.6% to close at $7.55. This move occurred on below-average volume, with approximately 2.92 million shares changing hands—about 35% less than the average daily volume of roughly 4.47 million. During the day, the price dipped as low as $7.44, following a previous close at $7.75 on Friday.

From a technical perspective, the outlook remains challenging. The current share price sits well below the 50-day moving average of $8.95 and even further beneath the 200-day moving average of $11.12. The considerable distance from its 52-week high of $23.20 underscores the broader erosion of confidence that has impacted the cannabis sector.

Second-Quarter Results: Mixed Signals

Investors continue to scrutinize the figures from Tilray's second quarter for fiscal 2026, released in early January. The company reported a GAAP net loss per share of -$0.41, an improvement from the -$0.99 loss recorded in the same quarter a year earlier. Revenue saw a 3% increase to $217.5 million, which the company noted was a record for a second fiscal quarter.

On an adjusted basis, the picture appeared somewhat brighter. The adjusted loss per share was -$0.02, compared to -$0.03 in the prior-year period. Excluding non-cash tax items, Tilray actually reported an adjusted earnings per share of $0.01. According to Public.com, this result surpassed the consensus estimate of -$0.06.

Another positive signal came from the operating performance, with adjusted EBITDA reaching $8.4 million. Management reaffirmed its full-year fiscal 2026 guidance for adjusted EBITDA, maintaining its target range of $62 to $72 million.

Structural Concerns: Dilution and Margins

Recent weekend analyses have brought structural issues back into focus. A report from Motley Fool highlighted that the number of outstanding shares has ballooned by 495% since Tilray's U.S. market debut in July 2018. This starkly contrasts with the mere 3% net revenue growth in the most recent quarter, fueling the ongoing debate over shareholder dilution.

Separately, Kavout calculated the net margin for the trailing twelve months at -252.6%. It is also worth noting that Tilray executed a 1:10 reverse stock split in early December 2025.

New Partnership Fails to Ignite Rally

The recent announcement of an exclusive, multi-year U.S. brewing and distribution partnership with the Carlsberg Group has so far done little to alter the stock's trajectory. Effective January 1, 2027, Tilray will produce, market, sell, and distribute beers including Carlsberg, Carlsberg Elephant, 1664, and Kronenbourg 1664 Blanc in the United States under an initial five-year agreement.

While Kavout pointed out that the beverage segment contributed approximately $241 million in revenue during fiscal 2025, this positive business development has not halted the stock's negative momentum.

Analyst Sentiment Remains Cautious

The prevailing mood among analysts continues to be one of caution. Data from MarketBeat shows a consensus rating of "Hold," based on 1 "Buy" recommendation, 6 "Hold" ratings, and 1 "Sell." The average price target stands at $13.33. A notable adjustment came from Roth MKM in January, which significantly reduced its price target from $20 to $10 while maintaining a "neutral" stance.

Market participants are now looking ahead to the next quarterly report, currently expected on April 8. This update will likely indicate whether Tilray can demonstrate further operational progress and sustain confidence in its full-year EBITDA target.